Brand-Name FDA-Approved Medications Referenced on altRx altRx's source materials also reference brand-name FDA-approved medications at separate listed price points: Mounjaro: Listed at $1,249 per month per altRx's source materials Ozempic: Listed at $1,149 per month per altRx's source materials Wegovy: Listed at $1,579 per month per altRx's source materials Zepbound: Listed at $1,249 per month per altRx's source materials According to altRx's published trademark notice, Wegovy is FDA-approved for weight loss, and Ozempic is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss at the discretion of a clinician
Presentations at the most recent ADA scientific sessions in 2024 included discussions of clear benefits to reduce liver fat in MASH (formerly called NAFLD) with tirzepatide (Loomba, NEJM, 2024) and a phase 2 trial with the triagonist (GLP-1/GIP/Glucagon), retatrutide (Sanyal, Nature Medicine, 2024)
GLP-1 Therapies Reshape Global Healthcare The global obesity crisis continues to intensify
In our cohort, 27% of the cohort discontinued naltrexone-bupropion due to side effects